This guidance document addresses a number of questions that users of the centralised procedure may have. It provides an overview of the European Medicines Agency’s position on issues, which are typically addressed during the course of pre-submission meetings.
The EMA emphasises the importance of pre-submission meetings between applicants and the EMA/(Co- ) Rapporteur. Pre-submission meetings (which should take place approximately 7 months prior to the anticipated date of submission of the application) are a vital opportunity for applicants to obtain procedural, regulatory, and legal advice from the EMA.
This guidance information and fruitful pre-submission meetings should enable applicants to submit applications, which are in conformity with the legal and regulatory requirements and which can be validated speedily.
Pre-submission meetings will also enable applicants to establish contact with the EMA staff closely involved with the application as it proceeds.
Comentarios